ABSTRACT
Neuroleptic malignant syndrome is rare in neurology practice. It may occur due to the use of high doses of antipsychotics. It requires intensive care follow-up due to its severe complications and has high mortality. Fever, rigidity, confusion, and respiratory distress are important symptoms of the condition. It is important to note that this disease should be considered in the differential diagnosis of patients with fever, especially after the coronavirus disease-2019 disease that emerged in 2019-2020, and whose fever does not decrease as an important symptom. For these reasons, we think that the presentation of this phenomenon will be useful.
Keywords: Neuroleptic malignant syndrome, fire height, intensive care
References
1
Erol A, Putgül G, Sert E, Mete L. Klozapin kullanımına bağlı nöroleptik malign sendrom ve ardışık katatoni: olgu sunumu [Clozapine-associated neuroleptic malignant syndrome followed by catatonia: a case report]. Turk Psikiyatri Derg 2013;24:140-4.
2
Kasantikul D, Kanchanatawan B. Neuroleptic malignant syndrome: a review and report of six cases. J Med Assoc Thai 2006;89:2155-60.
3
Baba O, Yamagata K, Tomidokoro Y, Tamaoka A, Itoh H, Yanagawa T, et al. Neuroleptic malignant syndrome in a patient with tongue cancer: a report of a rare case. Case Rep Dent 2013;2013:542130.
4
Rasmussen KG. Risk factors for neuroleptic malignant syndrome. Am J Psychiatry 1998;155:1639-40.
5
Wysokiński A. Intensive electroconvulsive therapy in drug resistant neuroleptic malignant syndrome - case report. Psychiatr Danub 2012;24:219-22.
6
Moscovich M, Nóvak FT, Fernandes AF, Bruch T, Tomelin T, Nóvak EM, et al. Neuroleptic malignant syndrome. Arq Neuropsiquiatr 2011;69:751-5.
7
Ananth J, Parameswaran S, Gunatilake S, Burgoyne K, Sidhom T. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 2004;65:464-70.
8
Tu MC, Hsiao CC. Amisulpride and neuroleptic malignant syndrome. Chang Gung Med J 2011;34:536-40.
9
Pereira YD, Srivastava A, Cuncoliencar BS, Naik N. Resolution of symptoms in neuroleptic malignant syndrome. Indian J Psychiatry 2010;52:264-6.
10
Amore M, Zazzeri N. Neuroleptic malignant syndrome after neuroleptic discontinuation. Prog Neuropsychopharmacol Biol Psychiatry 1995;19:1323-34.
11
Hayashi H, Kawakatsu S, Watanabe K, Fukasawa T, Otani K. Neuroleptic malignant syndrome complicated by massive intestinal bleeding in a patient with chronic renal failure. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:1225-7.
12
Nierenberg D, Disch M, Manheimer E, Patterson J, Ross J, Silvestri G, et al. Facilitating prompt diagnosis and treatment of the neuroleptic malignant syndrome. Clin Pharmacol Ther 1991;50:580-6.
13
Ording H, Ranklev E, Fletcher R. Investigation of malignant hyperthermia in Denmark and Sweden. Br J Anaesth 1984;56:1183-90.
14
Guzé BH, Baxter LR Jr. Current concepts. Neuroleptic malignant syndrome. N Engl J Med 1985;313:163-6.
15
Tsujimoto S, Maeda K, Sugiyama T, Yokochi A, Chikusa H, Maruyama K. Efficacy of prolonged large-dose dantrolene for severe neuroleptic malignant syndrome. Anesth Analg 1998;86:1143-4.
16
Peter SA, Autz A, Jean-Simon ML. Bromocriptine-induced schizophrenia. J Natl Med Assoc 1993;85:700-1.
